Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 7Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 2Recurrence 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 149Rituximab 104Peripheral Blood Stem Cell Transplantation 101fludarabine phosphate 100Filgrastim 72Mycophenolic Acid 67Cyclosporine 59Radiotherapy 58Whole-Body Irradiation 57Etoposide 55Tacrolimus 51Busulfan 50Antilymphocyte Serum 43Melphalan 41Methotrexate 37Cytarabine 27Cord Blood Stem Cell Transplantation 26fludarabine 25Bortezomib 24Methylprednisolone 23Carmustine 22sargramostim 21Flow Cytometry 19Dexamethasone 19Lenalidomide 18Granulocyte Colony-Stimulating Factor 18Vincristine 17Prednisone 17Bendamustine Hydrochloride 17aldesleukin 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × polatuzumab vedotin × Other hematologic neoplasm × Clear all
NCT04659044 2024-09-19

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Academic and Community Cancer Research United

Phase 2 Terminated
3 enrolled 11 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡